Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Frontiers in Medicine

Yoichi Tanaka¹  Eri Tsukagoshi¹  Yoshiro Saito² 

[1] Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan;null;

关键词: Stevens-Johnson syndrome;    toxic epidermal necrolysis;    pharmacogenomics;    implementation;    drug label;    guideline;   

DOI  :  10.3389/fmed.2021.644154

来源: Frontiers

【 摘 要 】

Drug-related Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse drug reactions, termed as idiosyncratic reactions; however, predicting their onset remains challenging. Pharmacogenomic information associated with SJS/TEN has accumulated on several drugs in the last 15 years, with clinically useful information now included on drug labels in several countries/regions or guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC) for implementation. However, label information might be different among countries. This mini-review summarizes pharmacogenomic information on drug labels of five drugs in six countries and compared descriptions of drug labels and CPIC guidelines. Finally, we discuss future perspectives of this issue. Pharmacogenomic information on drug labels is not well-harmonized across countries/regions, but CPIC guidelines are a scientifically sound goal for future pharmacogenomic implementation.

【 授权许可】

CC BY